"What matters is that someone owns the entire pathway for that product from identifying the unmet need through development, ...

This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.

Nitrosamine have been a problem in pharmaceutical manufacturing since approximately 2018, after the carcinogenicimpurities were found in statin drugs. Since then, regulators and pharmaceutical ...

Companies showcasing equipment and services at the event include Shilpa Biologicals (Booth 12J33), which is announcing the ...

Manufacturers are encouraged to treat resiliency policy as an actionable trend and proactively shape solutions rather than ...

The deal also gives Novartis exclusive options to license additional next-generation programs built on Abogen's proprietary ...

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...

Scarboro contends these findings should be treated as design information rather than as a sign that patients need more ...

In June 1937, a salesman for the S. E. Massengill Company reported demand in the southern states for sulfanilamide in liquid ...

In US regulatory news, the FDA opened applications for its Expedited IND Pilot on September 15. 1 The program pairs drug ...

The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...

Machine-readable digital standards integrated into LIMS, ELNs, and regulatory platforms reduce transcription risk, streamline ...